Medical/Pharmaceuticals

Polyplastics Expands DURACON (R) POM PM Series with New High-flow Grade for Medical and Healthcare Industry

TOKYO, Feb. 25, 2021 /PRNewswire/ -- The Polyplastics Group is expanding its DURACON (R) polyoxymethylene (POM) PM series portfolio with the development of a new high-flow grade for drug contact and delivery applications for the medical and healthcare market. The new grade, DURACON PM27S01N, offe...

2021-02-25 15:00 2833

Elekta appoints Johan Adebäck as Chief Financial Officer

STOCKHOLM, Feb. 25, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that Johan Adebäck has been appointed as permanent Chief Financial Officer with immediate effect. He has held the position of Acting CFO sinceJune 2, 2020. Prior to the Acting CFO position, Johan Adebäck had been Group Tr...

2021-02-25 14:52 5066

Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-β Agonist ASC41 for NASH

SHANGHAI, Feb. 24, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of nonalcoholic steatohepatitis (NASH), today announces the Investigational New Drug Application (IND) approval ...

2021-02-25 08:30 3025

WuXi Biologics Wins 2021 CMO Leadership Awards in All Six Core Categories

SHANGHAI, Feb. 25, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the company has been named a winner of the 2021 CMO Leadership Awards for a fourth year in a row. The company is proud to ...

2021-02-25 08:00 2142

Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2021

HONG KONG, Feb. 25, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for...

2021-02-25 05:16 10183

Game-Changing Wrinkle Reduction Device Receives Key Regulatory Clearance in Canada

Sofwave is crucial to your aesthetic practice. Learn Why! YOQNEAM, Israel, Feb. 25, 2021 /PRNewswire/ -- Sofwave Medical, the emerging leader of energy-based non-invasive, skin treatment aesthetic medical devices, announced today that it received clearance from Health Canada for its next-generat...

2021-02-25 01:00 1976

Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI

Insilico Medicine Achieves Industry First Nominating Preclinical Candidate for Idiopathic Pulmonary Fibrosis With Both Novel Drug Target and Novel Molecule Discovered by Artificial Intelligence HONG KONG, Feb. 25, 2021 /PRNewswire/ -- Insilico Medicine has demonstrated a breakthrough in Artifici...

2021-02-25 00:48 2772

First cancer centers begin using initial release of Elekta's MOSAIQ 3 series

ATLANTA, Feb. 25, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that several cancer centers are the early adopters of the company's first release in the MOSAIQ® 3* series. Featuring increased automation and simplified user interfaces, MOSAIQ 3 is designed to significantly reduce workflo...

2021-02-25 00:46 4938

Zymergen Appoints Global Finance Expert Enakshi Singh as Chief Financial Officer

EMERYVILLE, Calif., Feb. 24, 2021 /PRNewswire/ -- Biofacturing leader Zymergen  today announced it has promotedEnakshi (Ena) Singh to Chief Financial Officer. Singh has helped Zymergen close more than$1B in equity financing and $100M in debt since joining Zymergen as vice president of finance in 2...

2021-02-24 22:30 4961

VLP BioTech, Inc. Announces an Immunotherapy Designed for the Treatment of Chronic HBV/HDV Infections

-  VLP BioTech Has Developed a Vaccine-Based Viral-Entry-Inhibitor for the Treatment of Chronic HBV/HDV. -  The Vaccine-Based Treatment Has Significant Advantages Compared to a Peptide-Based, Entry-Inhibitor (Hepcludex). SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- VLP BioTech, Inc., a private, pre...

2021-02-24 22:00 3030

Occlutech announces Completion of Patient Enrolment in Pilot Study of Atrial Flow Regulator (AFR) in Patients with Heart Failure

SCHAFFHAUSEN, Switzerland, Feb. 24, 2021 /PRNewswire/ -- Occlutech, a privately-held company, announced today the completion of patient enrolment in its pilot study to assess safety and efficacy of the novel Atrial Flow Regulator (AFR) in heart failure (HF) patients (PRELIEVE trial). PRELIEVE is...

2021-02-24 20:41 2359

MedTech to Take Advantage of Digital Health Platform as a Service Model to Accelerate Digital Transformation across the Healthcare Industry

A proven, compliant platform can expedite market entry and optimize time and effort without building competencies internally, finds Frost & Sullivan SANTA CLARA, Calif., Feb. 24, 2021 /PRNewswire/ -- MedTech and Life Sciences companies are transitioning beyondbiopharmaceuticals, medical devices, ...

2021-02-24 20:02 1880

INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia

- Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions - QIAGEN's bioinformatic expertise raises predictive biomarker power in INOVIO's patient selection - First-in-class next genera...

2021-02-24 14:45 6155

Additional Positive Interim Results from Nanoform's Clinical Study

HELSINKI, Feb. 24, 2021 /PRNewswire/ -- Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced further positive interim results from its ongoing clinical study. The fast absorption data implies that small is powerful® and might offer viable alternatives to com...

2021-02-24 14:33 1302

Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA

SHANGHAI and HONG KONG, Feb. 24, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and onco...

2021-02-24 08:00 3087

US Court Grants MGI's Motion to Amend in Suit Against Illumina

SAN FRANCISCO, Feb. 24, 2021 /PRNewswire/ -- A judge in the U.S. District Court for the Northern District ofCalifornia has granted MGI's motion for leave to amend to add a new inequitable conduct defense of patent infringement lawsuit that Illumina filed against MGI inFebruary 2020 (Case No. 20-c...

2021-02-24 04:00 3669

New Research Highlights the Potential of Transforming Healthcare with Mobile EEG Brain Health Assessments

Recent publications in Frontiers of Neuroscience, Scientific Report and Neurophysiologie Clinique validate the use of Muse® as a mobile EEG device to measure brain health and performance at scale in real-world environments TORONTO, Feb. 24, 2021 /PRNewswire/ -- In a time with overburdened healthc...

2021-02-24 03:21 1574

ScImage Lauded by Frost & Sullivan for Its Cloud-based Enterprise Imaging Platform, PICOM365

Its seamless integration across imaging programs and tools give physicians single-platform access to all the tools needed to view and interpret images and videos from anywhere SANTA CLARA, Calif., Feb. 23, 2021 /PRNewswire/ -- Based on its recent analysis of the North American cloud-based enterp...

2021-02-23 22:00 1613

Rheumatology Clinical Researcher Professor David Hunter Joins George Clinical Scientific Leadership

OVERLAND PARK, Kan., Feb. 23, 2021 /PRNewswire/ -- David Hunter, MBBS, PhD, a renowned clinical researcher and rheumatology expert based inAustralia, has joined the scientific leadership of George Clinical, a global scientifically-backed clinical research organization. Professor Hunter's researc...

2021-02-23 22:00 1362

INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa

Phase 1B clinical trial is first study for Lassa fever conducted in Africa Goal is for vaccine to be available for emergency use as stockpile product following Phase 2 Progress on INO-4500 reflects INOVIO's focus on and continued commitment to the fight against infectious diseases Trial fully f...

2021-02-23 21:00 4953
1 ... 304305306307308309310 ... 397

Week's Top Stories